Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.
10.1007/s13238-017-0411-9
- Author:
Hua LI
1
;
Yangbing ZHAO
2
Author Information
1. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104-5156, USA.
2. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104-5156, USA. yangbing@upenn.edu.
- Publication Type:Journal Article
- Keywords:
T lymphocytes;
cancer adoptive immunotherapy;
chimeric antigen receptors;
gene editing;
gene therapy
- MeSH:
Cell Movement;
immunology;
Cell Proliferation;
Gene Expression;
Genetic Vectors;
chemistry;
metabolism;
Humans;
Immunotherapy, Adoptive;
methods;
Lymphocyte Activation;
Lymphocytes, Tumor-Infiltrating;
cytology;
immunology;
transplantation;
Neoplasms;
genetics;
immunology;
pathology;
therapy;
Patient Safety;
Receptors, Antigen, T-Cell;
chemistry;
genetics;
immunology;
Recombinant Fusion Proteins;
chemistry;
genetics;
immunology;
Signal Transduction;
Single-Chain Antibodies;
chemistry;
genetics;
T-Lymphocytes;
cytology;
immunology;
transplantation;
Treatment Outcome
- From:
Protein & Cell
2017;8(8):573-589
- CountryChina
- Language:English
-
Abstract:
Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment that has recently been undergoing rapid development. However, there are still some major challenges, including precise tumor targeting to avoid off-target or "on-target/off-tumor" toxicity, adequate T cell infiltration and migration to solid tumors and T cell proliferation and persistence across the physical and biochemical barriers of solid tumors. In this review, we focus on the primary challenges and strategies to design safe and effective CAR T cells, including using novel cutting-edge technologies for CAR and vector designs to increase both the safety and efficacy, further T cell modification to overcome the tumor-associated immune suppression, and using gene editing technologies to generate universal CAR T cells. All these efforts promote the development and evolution of CAR T cell therapy and move toward our ultimate goal-curing cancer with high safety, high efficacy, and low cost.
